Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Peter_DeYoung
|
| gptkbp:country |
gptkb:India
|
| gptkbp:foundedBy |
gptkb:Ajay_Piramal
|
| gptkbp:foundedYear |
2022
|
| gptkbp:headquartersLocation |
Mumbai, Maharashtra, India
|
| https://www.w3.org/2000/01/rdf-schema#label |
Piramal Pharma Limited
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:ISIN |
INE0DK501011
|
| gptkbp:numberOfEmployees |
~6000
|
| gptkbp:parentCompany |
gptkb:Piramal_Group
|
| gptkbp:products |
Consumer healthcare products
Pharmaceutical formulations Contract development and manufacturing Critical care products |
| gptkbp:stockExchange |
gptkb:NSE
BSE |
| gptkbp:subsidiary |
Piramal Consumer Products Division
Piramal Critical Care Piramal Pharma Solutions |
| gptkbp:website |
https://www.piramalpharma.com/
|
| gptkbp:bfsParent |
gptkb:Nandini_Piramal
gptkb:Piramal_Group gptkb:Peter_DeYoung gptkb:Piramal_Enterprises_Limited |
| gptkbp:bfsLayer |
7
|